In a randomized, controlled, dose-ranging 52-week study of the tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib among patients with moderate to severe active psoriatic arthritis, patients were randomly assigned to receive the agent at either 10 mg, 30 mg, or 60 mg once daily, or placebo. At week 16, patients advanced to either 30 or 60 mg of brepocitinib. At week 16, patients who had been receiving the 30 mg or 60 mg dose had greater American College of Rheumatology (ACR)20 response rates than those who had received placebo; psoriasis area and severity and disease activity were also improved. Response rates were maintained throughout the 52-week study period, and adverse events were mostly mild or moderate. These findings were published by Mease et al in Arthritis & Rheumatology.
May 25, 2023